Tinostamustine - Mundipharma EDO

Drug Profile

Tinostamustine - Mundipharma EDO

Alternative Names: Bendamustine-vorinostat fusion molecule; EDO S101; NL-101

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northlake International
  • Developer Mundipharma EDO
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in Switzerland (IV, Infusion)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (IV, Infusion)
  • 09 Mar 2018 Mundipharma EDO and M.D. Anderson Cancer Center plans a phase I trial for Glioblastoma (Newly diagnosed, Second-line therapy or greater) in USA in March 2018 (NCT03452930)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top